Loading organizations...
Entact Bio is a preclinical-stage biotechnology company developing precision medicines that enhance the function of beneficial proteins, based in Watertown, Massachusetts. The enterprise utilizes its proprietary Encompass platform to create chimeric molecules that leverage deubiquitinases to restore protein function for treating oncology, autoimmune conditions, and other hard-to-treat diseases. Operating under the leadership of Chief Executive Officer Victoria Richon, who previously held executive roles at Ribon Therapeutics and Sanofi, the firm emerged from stealth in 2023 after securing $81 million in Series A financing. This initial venture capital funding round was supported by a syndicate of prominent institutional investors, including Qiming Venture Partners USA, venBio Partners, Abingworth, 4BIO Capital, and Arkin Bio Ventures. Entact Bio was founded in 2021 by David Komander, David Sheppard, Jarrod Marto, Michael Clague, Sarah Buhrlage, Sylvie Urbe, and Ueli Nachbur.
Entact Bio has raised $81.0M across 1 funding round.
Key people at Entact Bio.
Entact Bio has raised $81.0M in total across 1 funding round.
Entact Bio has raised $81.0M across 1 funding round. Most recently, it raised $81.0M Series A in December 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2022 | $81M Series A | Anna French | 4BIO Capital, Abingworth, Foresite Capital, VenBio Partners, Arkin BIO Ventures, Brandon Capital, Janus Henderson Investors, Logos Capital, Surveyor Capital, Ueli Nachbur | Announced |
Key people at Entact Bio.
Entact Bio is a preclinical-stage biotechnology company developing ENTAC (enhancement-targeting chimeric) medicines, a novel class of precision small-molecule drugs that enhance the function of beneficial proteins by harnessing deubiquitinases (DUBs).[1][3][4] These drugs act as molecular matchmakers, recruiting DUBs to remove ubiquitin chains from target proteins, thereby extending their lifespan, relocating misplaced proteins, or altering their activity to treat diseases like cancer, autoimmune conditions, and genetic disorders.[1][3][5] The company serves patients underserved by current therapies that focus on blocking or degrading harmful proteins, using its proprietary Encompass platform—integrating AI-driven target discovery, DUB selection, and drug design—to advance multiple preclinical programs.[1][2][4] Launched in 2022 with an $81 million Series A led by Qiming Venture Partners USA and venBio Partners, Entact demonstrates strong early momentum through data unification via tools like Quilt, reducing lookup times by 90% and enabling scalable R&D for IND filings.[1][2][5]
Entact Bio emerged from stealth in December 2022, founded in 2019–2020 by an international team of scientists from the Dana-Farber Cancer Institute (US), University of Liverpool (UK), and Walter and Eliza Hall Institute of Medical Research (Australia), experts in DUB biochemistry, chemical biology, disease biology, and small-molecule drug development.[1][3][5] The idea stemmed from their deep roots in DUB research, recognizing an untapped opportunity to leverage these enzymes for protein enhancement rather than degradation, expanding treatable targets beyond traditional modalities.[1][4] Victoria Richon, a biotech veteran with prior CEO roles at Ribon Therapeutics and executive positions at Sanofi, Epizyme, and Merck, joined as CEO to lead commercialization.[1][5] Early traction included the $81 million Series A, platform buildout, and integration of 30+ public ubiquitin datasets alongside internal data for collaborative R&D.[1][2][5]
Entact Bio stands out in biotech through its focus on protein enhancement, contrasting with degradation-focused platforms like PROTACs.
Entact rides the protein modulation wave in biotech, shifting from degradation (e.g., PROTACs) to enhancement, unlocking "undruggable" beneficial proteins for diseases like cancer and autoimmunity where current treatments fall short.[1][5] Timing aligns with advances in AI-driven drug discovery, DUB biology, and computational chemistry, amplified by post-2020 funding for novel modalities amid stalled traditional small-molecule pipelines.[1][4] Favorable market forces include rising demand for precision medicines, regulatory interest in ubiquitin pathways, and investor appetite for platform companies—evidenced by Entact's quick $81M raise.[1][5] By expanding the "druggable universe," Entact influences the ecosystem, inspiring hybrid modalities and collaborative data tools that accelerate preclinical-to-clinical translation.[2][4]
Entact Bio is poised for milestone advances, with its Encompass platform driving multiple ENTACs toward IND filings in oncology and immunology, potentially yielding first-in-class therapies by 2027–2028.[1][2][5] Key trends like AI integration, multi-omics data unification, and DUB-focused partnerships will propel growth, while scaling data infrastructure positions it for Big Pharma alliances or Series B funding.[2][4] Its influence may evolve from preclinical innovator to ecosystem shaper, redefining protein therapeutics and delivering options for patients beyond degradation paradigms—transforming how biotech enhances, rather than just inhibits, biology.[1][3]
Entact Bio has raised $81.0M in total across 1 funding round.
Entact Bio's investors include Anna French, 4BIO Capital, Abingworth, Foresite Capital, venBio, Arkin Bio Ventures, Brandon Capital, Janus Henderson Investors, Logos Capital, Surveyor Capital, Ueli Nachbur.
